Read by QxMD icon Read

Therapeutic Drug Monitoring

Jennifer Le, Brenda Poindexter, Janice E Sullivan, Matthew Laughon, Paula Delmore, Martha Blackford, Ram Yogev, Laura P James, Chiara Melloni, Barrie Harper, Jeff Mitchell, Daniel K Benjamin, Felix Boakye-Agyeman, Michael Cohen-Wolkowiez
BACKGROUND: Dried blood spot (DBS) is a practical sampling strategy for pharmacokinetic studies in neonates. The utility of DBS to determine the population pharmacokinetics (pop-PK) of ampicillin, as well as accuracy versus plasma samples, was evaluated. METHODS: An open-label, multicenter, opportunistic, prospective study was conducted in neonates. Ampicillin concentrations from plasma and DBS (CONCPlasma and CONCDBS) were measured by liquid chromatographic tandem mass spectrometry and analyzed using pop-PK and statistical (including transformation) approaches...
December 21, 2017: Therapeutic Drug Monitoring
Claudia Felipe, Alexandra Ferreira, Adrieli Bessa, Tamiris Abait, Juliana D Perez, Dulce Elena Casarini, Jose Medina-Pestana, Helio Tedesco
BACKGROUND: This study investigates the adequacy of initial everolimus (EVR) dose, with and without calcineurin inhibitors (CNI), in kidney transplant recipients. METHODS: This retrospective cohort analysis involved data from 305 kidney transplant recipients participating in three randomized trials receiving reduced dose cyclosporin A (CsA) combined with EVR 0.75 mg BID (CSA/EVR0.75, N = 32) or 1.5 mg BID (CSA/EVR1.5, N = 31), reduced dose tacrolimus (TAC) combined with EVR 1...
December 21, 2017: Therapeutic Drug Monitoring
Remy B Verheijen, Bas Thijssen, Hilde Rosing, Jan H M Schellens, Lianda Nan, N Venekamp, Jos H Beijnen, Neeltje Steeghs, Alwin D R Huitema
BackgroundPazopanib is an angiogenesis inhibitor approved for renal cell carcinoma and soft tissue sarcoma. Studies indicate that treatment with pazopanib could be optimized by adapting the dose based on measured pazopanib plasma concentrations.MethodsWe describe the validation and clinical application of a fast and straightforward method for the quantification of pazopanib in human plasma for the purpose of therapeutic drug monitoring and bioanalytical support of clinical trials.Stable isotopically labeled C,H3-pazopanib was used as internal standard...
December 18, 2017: Therapeutic Drug Monitoring
Handley Sa, Silk Sw Fisher, Subramaniam K, Flanagan Rj
BACKGROUND: Plasma and serum are often used interchangeably for therapeutic drug monitoring purposes, and concentrations of some drugs are reported to be lower in serum than plasma when collected into blood collection tubes containing a gel separator. Therapeutic drug monitoring is recommended for clozapine, although few studies have compared concentrations between plasma and serum. Therefore, we investigated the comparability of dipotassium EDTA human plasma and serum from blood collection tubes containing a gel separator for the measurement of clozapine and norclozapine...
December 12, 2017: Therapeutic Drug Monitoring
Rani George, Alison Haywood, Sohil Khan, Mirjana Radovanovic, Joshua Simmonds, Ross Norris
High-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) is commonly used for quantitation of analytes in biological matrices, due to the selectivity, sensitivity, and high throughput offered by this technique. However, the presence of both suppression and enhancement of ionization (SEI) by matrix components is an increasingly recognized impediment to accurate results. The existence of SEI indicates that ionization efficiency is a result of the chemical environment seen by both the analyte and internal standard during ion formation...
December 11, 2017: Therapeutic Drug Monitoring
Simone Castoldi, Valeria Cozzi, Sara Baldelli, Serena Fucile, Emilio Clementi, Dario Cattaneo
BACKGROUND: An enzymatic immunoassay is under development by ARK Diagnostics, Inc. for the quantification of plasma concentrations of linezolid (LZD). In the present study, the authors aimed to assess the performance of this immunoassay using a validated HPLC-UV method as reference. METHODS: Within- and between-day in vitro inaccuracy and imprecision of the ARK LZD assay were firstly tested using spiked quality controls (QC) provided by the kit manufacture. Subsequently, the performance of the immunoassay was verified in vivo by analyzing 170 trough LZD plasma samples from patients on antibiotic therapy...
December 4, 2017: Therapeutic Drug Monitoring
Shenghui Mei, Jiaqing Wang, Di Chen, Leting Zhu, Ming Zhao, Xin Hu, Li Yang, Zhigang Zhao
BACKGROUND: Various immunoassays have been used for cyclosporine A (CsA) analysis in human whole blood; however, they could not fully satisfy the requirements of criteria for accuracy and specificity in CsA measurement. The liquid chromatography tandem mass spectrometry is a gold method for CsA analysis. The aim of the study was to develop and validate an ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method for CsA analysis and establish its agreement with an antibody-conjugated magnetic immunoassay (ACMIA) in clinical sample analysis...
December 4, 2017: Therapeutic Drug Monitoring
Eugènia Santacana, Lorena Rodríguez-Alonso, Ariadna Padullés, Jordi Guardiola, Francisco Rodríguez-Moranta, Katja Serra, Jordi Bas, Francisco Morandeira, Helena Colom, Núria Padullés
BACKGROUND: Infliximab (IFX) trough levels vary markedly between patients with inflammatory bowel disease (IBD), which is important for clinical response. The aim of this study was to evaluate the performance of previously developed population pharmacokinetic models in IBD patients for dose individualization for Crohn's disease and ulcerative colitis in our clinical setting. METHODS: The authors collected 370 trough levels prospectively from 100 adult IBD patients who were undergoing IFX treatment between July 2013 and August 2016...
December 1, 2017: Therapeutic Drug Monitoring
A Begeman, E J F Franssen
BACKGROUND: The number of reports of serious adverse effects and intoxication after the use of the new drug 4-fluoroamphetamine (4-FA) increases. At the Emergency Department of the OLVG-Oost Hospital in Amsterdam an on-site drug test, the Triage® TOX Drug Screen, is available to assist in a rapid diagnosis. In less urgent cases, an EMIT® II Plus immunoassay is used to determine semi-quantitatively the presence of drugs of abuse. The antibodies in these immunoassays are designed to detect classic drugs of abuse and its urinary metabolites...
November 29, 2017: Therapeutic Drug Monitoring
Alain G Verstraete, Raül Rigo-Bonnin, Pierre Wallemacq, Michael Vogeser, Andre Schuetzenmeister, Christian Schmiedel, Maria Shipkova
BACKGROUND: The precise monitoring of everolimus, an immunosuppressant drug, is vital for transplant recipients due to its narrow therapeutic range. This study evaluated the analytical performance of a new electrochemiluminescence immunoassay (ECLIA) for everolimus concentrations in whole blood. METHODS: Accuracy, imprecision, and sensitivity studies for the Roche Elecsys everolimus ECLIA were performed at five European laboratories. The ECLIA was compared with liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods, as well as the Quantitative Microsphere System (QMS) everolimus assay...
November 28, 2017: Therapeutic Drug Monitoring
Azucena Aldaz, Natalia Alzueta, César Viteri
BACKGROUND: Evaluate the effect of concomitant antiepileptic therapy on levetiracetam (LEV) pharmacokinetics. METHODS: A 6-year retrospective observational study. Patients were grouped according to the antiepileptic drug (AED) used as concomitant medication: Group A, LEV in monotherapy; Group B, LEV + enzyme-inducing antiepileptic drugs (EIAEDs) and Group C, LEV + non-enzyme-inducing antiepileptic drugs (NEIAEDs). Apparent oral LEV clearance (LEV CL/F) and basal serum LEV concentrations (LEV C0) were compared among the different groups by analysis of variance (ANOVA)...
November 23, 2017: Therapeutic Drug Monitoring
Claudia Lanvers-Kaminsky, Andrea Rüffer, Gudrun Würthwein, Joachim Gerss, Massimo Zucchetti, Andrea Ballerini, Andishe Attarbaschi, Petr Smisek, Christa Nath, Samiuela Lee, Sara Elitzur, Martin Zimmermann, Anja Möricke, Martin Schrappe, Carmelo Rizzari, Joachim Boos
BACKGROUND: In the international AIEOP-BFM ALL 2009 trial, asparaginase (ASE) activity was monitored after each dose of pegylated E. coli ASE (PEG-ASE). Two methods were used: the AHA test and MAAT. As the latter method overestimates PEG-ASE activity because it calibrates using E. coli ASE, method comparison was performed using samples from the AIEOP-BFM ALL 2009 trial. METHODS: PEG-ASE activities were determined by MAAT and AHA test in two sets of samples (1st set: 630 samples; 2nd set: 91 samples)...
November 23, 2017: Therapeutic Drug Monitoring
Hyeon Jeong Suh, Inho Kim, Joo-Youn Cho, Sang-In Park, Seo Hyun Yoon, Joo-Hee Hwang, Ji Yun Bae, Jeong-Ok Lee, Youngil Koh, Kyoung-Ho Song, Pyoeng Gyun Choe, Kyung-Sang Yu, Eu Suk Kim, Hong Bin Kim, Soo-Mee Bang, Nam Joong Kim, Myoung-Don Oh, Sang Hoon Song, Wan Beom Park
BACKGROUND: Therapeutic drug monitoring (TDM) of posaconazole is usually performed one week after starting the drug because of its long half-life. However, previous studies showed that measuring the posaconazole plasma concentration (PPC) on day 3 is effective for predicting steady-state levels. The purpose of this study was to evaluate the relevance of early TDM (day 3) of posaconazole for achieving an optimal PPC. METHODS: This prospective study was conducted from September 2014 to August 2016...
November 16, 2017: Therapeutic Drug Monitoring
Choong Eva, Uppugunduri Chakradhara Rao Satyanarayana, Marino Denis, Kuntzinger Melanie, Doffey-Lazeyras Fabienne, Lo Piccolo Rodolfo, Chalandon Yves, Peters Christina, Daali Youssef, Ansari Marc
BACKGROUND: Busulfan (Bu) is an alkylating agent used as part of the conditioning regimen in pediatric patients before hematopoietic stem cell transplantation (HSCT). Despite intravenous (IV) administration and dosing recommendations based on age and weight, reports have revealed interindividual variability in Bu pharmacokinetics and the outcomes of HSCT. In this context, adjusting doses to Bu's narrow therapeutic window is advised. We aimed to assess the utility of therapeutic drug monitoring (TDM) of Bu in children, the reliability of Bu quantification methods, and its stability in plasma when stored for up to five years...
November 15, 2017: Therapeutic Drug Monitoring
Mieke Carlier, Alexandre Athanasopoulos, Daniëlle Borrey, Pieter Colin, Frédéric Cotton, Raphael Denooz, Hugo Neels, Isabel Spriet, Timothy Ghys, Alain G Verstraete, Veronique Stove
No abstract text is available yet for this article.
November 14, 2017: Therapeutic Drug Monitoring
Nicolas Fabresse, Bénédicte Devictor, Christel Pissier, Hervé Chambost, Bruno Lacarelle, Gérard Michel, Caroline Solas
BACKGROUND: The aim of this study was to investigate the correlation between 7-hydroxymethotrexate (7-OHMTX) and creatinine and to evaluate the predictive value of 7-OHMTX levels on delayed elimination at 24 and 48 hours. In addition, differences in methotrexate (MTX), 7-OHMTX levels, and MTX metabolism using the ratio MTX/7-OHMTX were determined according to age. METHODS: The authors included a total of 106 cycles, corresponding to 33 patients (mean age: 9.8 years, range: 2-18 years) suffering from acute lymphoblastic leukemia, non-Hodgkin lymphoma and osteosarcoma and receiving high-dose MTX (HD-MTX)...
November 8, 2017: Therapeutic Drug Monitoring
Simona Pichini, Renata Solimini, Paolo Berretta, Roberta Pacifici, Francesco Paolo Busardò
Illicit fentanyl and its analogues are very dangerous synthetic opioids, with high abuse potential and severe adverse effects including coma and death. They are used as adulterants in street heroin, cocaine, and methamphetamine, or as heroin substitutes sold to unaware users with a high risk of overdoses. Fentanyl and its analogues have also been identified in counterfeit medicinal products, such as oxycodone, hydrocodone, and alprazolam tablets, or as components of speedball mixtures together with cocaine or other stimulants...
November 8, 2017: Therapeutic Drug Monitoring
Elsie Rizk, Allison D Wilson, Michelle U Murillo, David R Putney, Bcps-Aq Cardiology
BACKGROUND: Vascular surgery patients often require anticoagulation with intravenous unfractionated heparin monitored via anti-Xa levels or the activated partial thromboplastin time (aPTT). This study compares the two monitoring strategies in terms of major bleeding events in the vascular surgery population. METHODS: This was a single center, retrospective study that included patients treated with a pharmacy-managed heparin protocol monitored by either anti-Xa or aPTT after vascular surgery...
November 8, 2017: Therapeutic Drug Monitoring
Simone H J van den Elsen, Lisette M Oostenbrink, Scott K Heysell, Daiki Hira, Daan J Touw, Onno W Akkerman, Mathieu S Bolhuis, Jan-Willem C Alffenaar
BACKGROUND: Therapeutic drug monitoring is useful in the treatment of tuberculosis to assure adequate exposure, minimize antibiotic resistance, and reduce toxicity. Salivary therapeutic drug monitoring could reduce the risks, burden, and costs of blood-based therapeutic drug monitoring. This systematic review compared human pharmacokinetics of anti-tuberculosis drugs in saliva and blood to determine if salivary therapeutic drug monitoring could be a promising alternative. METHODS: On December 2, 2016, PubMed and the Institute for Scientific Information Web of Knowledge were searched for pharmacokinetic studies reporting human salivary and blood concentrations of anti-tuberculosis drugs...
November 8, 2017: Therapeutic Drug Monitoring
Masayuki Chuma, Makoto Makishima, Toru Imai, Naohiro Tochikura, Shinichiro Suzuki, Tsukasa Kuwana, Nami Sawada, Tomohide Komatsu, Takako Sakaue, Norikazu Kikuchi, Yoshikazu Yoshida, Kosaku Kinoshita
BACKGROUND: Appropriate initial dosing of vancomycin (VCM) is important in improving survival and in preventing nephrotoxicity in critically ill patients, but the potential relationship between initial VCM trough levels and early-onset nephrotoxicity remains unclear. We examined the relationship between initial VCM trough levels and early-onset VCM-associated nephrotoxicity. METHODS: We performed a retrospective study of patients who had therapeutic drug monitoring of VCM with initial trough levels within 4 days after the beginning of VCM administration...
October 31, 2017: Therapeutic Drug Monitoring
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"